POLB.L

Poolbeg Pharma PLC [POLB.L] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

POLB.L Stock Summary

The Moving Average Convergence Divergence (MACD) for POLB.L recently turned positive (within last 10 days).

Top 10 Correlated ETFs

POLB.L

Top 10 Correlated Stocks

POLB.L

In the News

POLB.L Financial details

Company Rating

Neutral

Market Cap

49M

Income

Revenue

Book val./share

0.03

Cash/share

0.03

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

25 Mar 2024

P/E

Forward P/E

PEG

P/S

P/B

P/C

345

P/FCF

-9.72

Quick Ratio

16.76

Current Ratio

17.76

Debt / Equity

LT Debt / Equity

EPS (TTM)

EPS next Y

EPS next Q

EPS this Y

27.03%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-41.94%

SMA20

SMA50

11.11%

SMA100

11.11%

Inst Own

Inst Trans

ROA

-24%

ROE

-23%

ROC

-0.27%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

Shs Float

Target Price

52W Range

6.38-12.1

52W High

-13.75%

52W Low

+72.5%

RSI

Rel Volume

0.97

Avg Volume

2.01M

Volume

1.95M

Perf Week

4.55%

Perf Month

13.11%

Perf Quarter

53.33%

Perf Half Y

47.02%

Beta

2.263

Volatility

0.18%, 0.35%

Prev Close

4.02%

Price

10.35

Change

3.5%

POLB.L Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2021-12-31	2022-12-31
	2.02K	2.02K
Revenue per share	0	0
Net income per share	-0.01	-0.01
Operating cash flow per share	-0.01	-0.01
Free cash flow per share	-0.01	-0.01
Cash per share	0.07	0.03
Book value per share	0.07	0.04
Tangible book value per share	0.07	0.03
Share holders equity per share	0.07	0.04
Interest debt per share	0	0
Market cap	30.14M	30.25M
Enterprise value	9.19M	14.06M
P/E ratio	-12.9	-6.46
Price to sales ratio	0	0
POCF ratio	-14.04	-6.93
PFCF ratio	-13.53	-6.09
P/B Ratio	1.33	1.65
PTB ratio	1.33	1.65
EV to sales	0	0
Enterprise value over EBITDA	-3.96	-2.83
EV to operating cash flow	-4.28	-3.22
EV to free cash flow	-4.13	-2.83
Earnings yield	-0.08	-0.15
Free cash flow yield	-0.07	-0.16
Debt to equity	0	0
Debt to assets	0	0
Net debt to EBITDA	9.04	3.26
Current ratio	48.98	17.76
Interest coverage	0	0
Income quality	0.92	0.91
Dividend Yield	0	0
Payout ratio	0	0
Sales general and administrative to revenue	0	0
Research and developement to revenue	0	0
Intangibles to total assets	0.07	0.11
Capex to operating cash flow	0.04	0.14
Capex to revenue	0	0
Capex to depreciation	-4.5	-22.96
Stock based compensation to revenue	0	0
Graham number	0.11	0.09
ROIC	-0.11	-0.27
Return on tangible assets	-0.11	-0.27
Graham Net	0.07	0.03
Working capital	21.02M	16.19M
Tangible asset value	21.02M	16.19M
Net current asset value	21.02M	16.19M
Invested capital	0	0
Average receivables	0	734K
Average payables	0	702K
Average inventory	0	0
Days sales outstanding	0	0
Days payables outstanding	8.88K	13.56K
Days of inventory on hand	0	0
Receivables turnover	0	0
Payables turnover	0.04	0.03
Inventory turnover	0	0
ROE	-0.1	-0.26
Capex per share	0	0

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2021-06-30	2022-06-30	2022-12-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0
Net income per share	0	0	-0.01	0
Operating cash flow per share	0	0	0	0
Free cash flow per share	0	0	-0.01	0
Cash per share	0	0.04	0.03	0.03
Book value per share	0	0.04	0.04	0.03
Tangible book value per share	0	0.04	0.03	0.03
Share holders equity per share	0	0.04	0.04	0.03
Interest debt per share	0	0	0	0
Market cap	0	26.5M	30.25M	41.5M
Enterprise value	-23.23M	7.61M	14.06M	27.38M
P/E ratio	0	-4.12	-2.46	-5.73
Price to sales ratio	0	0	0	0
POCF ratio	0	-15.87	-12.15	-20.64
PFCF ratio	0	-12.9	-11.2	-20.02
P/B Ratio	0	1.25	1.65	2.51
PTB ratio	0	1.25	1.65	2.51
EV to sales	0	0	0	0
Enterprise value over EBITDA	0	-4.06	-4.18	-12.19
EV to operating cash flow	0	-4.55	-5.65	-13.62
EV to free cash flow	0	-3.7	-5.2	-13.21
Earnings yield	0	-0.06	-0.1	-0.04
Free cash flow yield	0	-0.08	-0.09	-0.05
Debt to equity	0	0	0	0
Debt to assets	0	0	0	0
Net debt to EBITDA	0	10.09	4.81	6.28
Current ratio	175.07	24.28	17.76	29.13
Interest coverage	0	0	0	0
Income quality	0	1.04	0.81	1.11
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	0
Research and developement to revenue	0	0	0	0
Intangibles to total assets	0.06	0.09	0.11	0.13
Capex to operating cash flow	0	0.23	0.09	0.03
Capex to revenue	0	0	0	0
Capex to depreciation	0	-29.62	-16.31	-4.77
Stock based compensation to revenue	0	0	0	0
Graham number	0	0.06	0.07	0.05
ROIC	0	-0.08	-0.18	-0.14
Return on tangible assets	0	-0.08	-0.18	-0.12
Graham Net	0	0.04	0.03	0.03
Working capital	23.1M	19.25M	16.19M	14.38M
Tangible asset value	22.88M	19.25M	16.19M	14.38M
Net current asset value	22.88M	19.25M	16.19M	14.38M
Invested capital	0	0	0	0
Average receivables	0	0	1.07M	864.5K
Average payables	0	0	896.5K	545K
Average inventory	0	0	0	0
Days sales outstanding	0	0	0	0
Days payables outstanding	0	5.73K	6.69K	858.46
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	0
Payables turnover	0	0.02	0.01	0.1
Inventory turnover	0	0	0	0
ROE	0	-0.08	-0.17	-0.11
Capex per share	0	0	0	0

POLB.L Frequently Asked Questions

What is Poolbeg Pharma PLC stock symbol ?

Poolbeg Pharma PLC is a GB stock and trading under the symbol POLB.L

What is Poolbeg Pharma PLC stock quote today ?

Poolbeg Pharma PLC stock price is $10.35 today.

Is Poolbeg Pharma PLC stock public?

Yes, Poolbeg Pharma PLC is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 2.01M
Market Capitalization 49M
Employee 12
CEO Dr. Jeremy Skillington Ph.D.
Headquarters London,GB
IPO Date 2021-07-19
Website https://www.poolbegpharma.com

Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program. In addition, it is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.